General description
INN
Glecaprevir + pibrentasvir
Medicine type
Chemical agent
EML status history
First added in 2019
(TRS
1021)
for
Chronic hepatitis C
Changed in 2019
(TRS
1021)
for
Chronic hepatitis C
Changed in 2019
(TRS
1021)
for
Chronic hepatitis C
Changed in 2019
(TRS
1021)
for
Chronic hepatitis C
Therapeutic equivalent for
Wikipedia
DrugBank
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
- Oral > Solid: 100 mg + 40 mg tablet
Indications